RxDoctor Payments Data

Masroor Haq, MD

Psychiatry · Auburn Hills, MINPI 1417064502

Payments from drug & device makers

$508in general payments, 2019–2025

Across 24 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$189
  • Teva Pharmaceuticals USA, Inc.$112
  • Otsuka America Pharmaceutical, Inc.$69
  • Alkermes, Inc.$47
  • Neurocrine Biosciences, Inc.$18
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$16
  • plus $56 from 4 others

What the payments were for

  • Food & beverage$40880%
  • Education$10020%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$508 in reported general payments places this provider in the 65th percentile of 1,166 psychiatry providers in Michigan.

See all psychiatry providers in Michigan

Medicare billing

Part B allowed, 2024
$84,092
Medicare patients
145
Services billed
1,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate99$322,476
Abilify MaintenaAripiprazole30$81,606
LybalviOlanzapine/Samidorphan Malate21$31,886
VivitrolNaltrexone Microspheres15$25,214
Fluphenazine Hcl225$18,435
Chlorpromazine Hcl62$16,699
Divalproex Sodium ErDivalproex Sodium307$15,680
Olanzapine OdtOlanzapine113$9,475
TrintellixVortioxetine Hydrobromide19$8,975
Haloperidol268$7,323
Paliperidone ErPaliperidone37$6,797
Quetiapine Fumarate410$6,330
Clozapine154$6,229
Haloperidol Decanoate120$4,831
Olanzapine275$4,649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$189$322,47699 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$69$81,60630 claims
Alkermes, Inc.Lybalvi, Vivitrol$47$57,10036 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$14$8,97519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,166 psychiatry providers in Michigan.

Other psychiatry in Auburn Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →